Obesity, COVID-19 and immunotherapy: the complex relationship!

Carmine Finelli*1,2

1Department of Internal Medicine, Ospedale Cav R Apicella, ASL Napoli 3 Sud, Via di Massa, 1, 80040 Pollena, Napoli, Italy
2COVID Hospital Boscotrecase, ASL Napoli 3 Sud, Via Lenza, 3, 80042 Boscotrecase, Napoli, Italy

*Author for correspondence: carminefinelli74@yahoo.it

“...It is important to understand how obesity shapes immune responses and how obesity can change both the responses to immunotherapy and the potential toxicity. Therefore, all this suggests a surprisingly positive association between obesity, COVID-19 and immunotherapy.”

First draft submitted: 15 June 2020; Accepted for publication: 8 July 2020; Published online: 17 July 2020

Keywords: COVID 19 • immune checkpoint inhibitors • immunomodulation • immunopathology • immunotherapy • inflammatory cytokine neutralization • obesity

The coronavirus disease 2019 (COVID-19) is the third known coronavirus after SARS-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV) that was first described in late December 2019, until the epidemic began in Wuhan, China, and induces extreme respiratory disease and human pneumonia-like infection [1]. The pandemic spread of novel coronavirus (COVID-19) has been declared a global health emergency by the WHO.

Older adults and people of all ages who may have significant underlying health conditions – associated with obesity – could be at increased risk from COVID-19 for acute disease. Although general obesity is a risk factor for many disorders, several clinical trials have found that the concentration of visceral fat is more strongly related to different health problems, such as coronary disorders, insulin resistance and Type 2 diabetes mellitus [2]. Asthma, chronic lung disorder and cardiovascular disease are the main three health disorders for those infected with COVID-19.

Obesity & COVID-19

It is still too premature to have concrete data to support this in this pandemic, it is fair to expect that certain patients with obesity – particularly extreme obesity with a BMI over 40 – may have multiple health issues connected to obesity that could be linked to a more severe COVID-19 disease pathway. In the intensive care setting, patients with severe obesity are typically a more challenging population to manage and can struggle to survive if they undergo a significant illness, especially a respiratory infection such as COVID-19. For example, asthma, restrictive lung disease or obstructive sleep apnea could influence the respiratory function of obese patients [3]. Many obese patients experience at least one comorbidity linked to obesity, with Type 2 diabetes and cardiovascular disease being the most severe. Many obesity-related comorbidity include hyperlipidemia, chronic kidney failure, cancer with a cancer history and nonrheumatoid arthritis. This list of chronic diseases details the number of disorders we see every day among our patients that provide obesity treatment [4].

Therefore, obesity poses an elevated risk of severe infection with COVID-19, which may contribute to the need for mechanical ventilation in intensive care units and in the high incidence of mortality with premature death [5]. There are several underlying mechanisms: alteration in respiratory performance, involvement in comorbidities such as diabetes, hypertension, asthma or obstructive sleep apnea, inevitably insufficient and abnormal immunological responses, likely exacerbated by ectopic intrathoracic fat depots. Such results need improved prevention and curative interventions in obese patients in order to reduce the likelihood of relapse to an adverse outcome in COVID-19 cases. Obesity assumes a significant part in the pathogenesis of infection with COVID-19. Indeed, the immune
system, which is a main factor in COVID-19 pathogenesis, also plays a key role in inflammation of obesity-induced adipose tissue [6].

We also think it is very significant, and especially with regard to COVID-19, that people who have increased waistlines are likely to have elevated inflammatory markers sometimes. For example, an overactive immune system can result from the so-called inflammatory outbreak, and those individuals with increased waistlines may have elevated levels of inflammatory markers such as CRP, IL-6 or IL-1 [7]. In fact, the understanding of adipose tissue as an inert storage depot started to shift. Nevertheless, evidence began to accumulate that obesity, and especially visceral fat, is correlated with low-grade inflammation due to the elevated production of multiple adipocyte pro-inflammatory cytokines and their related macrophages. Some of those cytokines were often named ‘adipokines’, like leptin, TNF-α, IL-6 [2]. Which is as the theory of obesity blends magnificently with the developing inflammatory theory of COVID-19 pathology, it also links evidence of higher morbidity and mortality in marginalized ethnic and socio-economic groups where food deprivation, obesity and metabolic syndrome are still common [8].

COVID-19 immunopathology & immunotherapy

Immunotherapy is an important method of treatment to combat viral infections. Most attempts at immunotherapy have been effective in combating related COVID-19 viruses such as SARS-CoV and MERS-CoV, another coronavirus. Many vaccinations and applications for monoclonal antibody are the key approaches in this context. In addition, according to current evidence in the battle toward viral infections such as Ebola, influenza, SARS and MERS, plasma exchange will possibly reduce the viral load and mortality of diseases [9,10].

For all SARS-CoV and SARS-CoV-2 viruses, reaching the host cells is regulated by receptor-binding domain (RBD) association for S protein on the outer-membrane of the virus and angiotensin-converting enzyme 2 on the cell. Such proteins will also be the key possible targets for immunotherapy [1,7]. The awareness of MERS-CoV and SARS-CoV immunotherapies in recent years may expand prospects for successful use of the same therapies for novel coronavirus [3].

As can be seen by the fairly strong identification of RBD in COVID-19 and SARS-CoV, new monoclonal antibodies that could directly attach to COVID-19 RBD need to be established. Some of the most powerful SARS-CoV-specific neutralizing antibodies (e.g., m396, CR3014) targeting the SARS-CoV angiotensin-converting enzyme 2 binding site failed to attach COVID-19 spike protein, suggesting that the variation in SARS-CoV RBD and COVID-19 is distinct [7].

Assuming that both SARS-CoV and COVID-19 have the same virus entry receptor, possible biotherapeutics to inhibit SARS entry may be extrapolated for COVID-19 application. Monoclonal antibodies are favored by immunotherapy strategies to prevent the virus’ attachment or entry because of their precision, purity, low risk of blood-borne pathogen infection and protection compared with serum therapy and preparations for intravenous immunoglobulins [3].

The positive findings in monoclonal antibodies attacking spike protein in SARS-CoV and MERS-CoV motivate researchers to use it in combating COVID-19. Monoclonal antibody mixture or the combination of multiple monoclonal antibodies that identify various epitopes on the viral surface may help to neutralize the virus [3].

Many targets that appear important in immunotherapy of COVID-19 are cytokines. The specificity of IL-6 in COVID-19 among cytokines comes from the fact that increased IL-6 is associated with the intensity of the inflammatory cytokine storms. Therefore, targeting tocilizumab and siltuximab monoclonal antibodies to IL-6 and its receptor (IL-6R) could alleviate cytokine-related symptoms in serious COVID-19 patients [11] and in obese patients with COVID-19 who may have elevated levels of inflammatory markers such as IL-6.

Analysis of T cells in obese mice has led researchers to recognize that most of them are ‘depleted’, a concept of immunology that suggests slow proliferation and that they do not produce chemical messengers for contact with other immune cells [12]. Moreover, in obesity, T cells are thought to release higher levels of programmed cell death-1 (PD-1) protein, which prevents the killing of tumor cells by cytotoxic T cells, thereby facilitating the development and growth of tumors [13]. Immunotherapy researchers are aware of PD-1 and it is PD-L1 ligand and a range of ‘immune checkpoint inhibitors’ have been developed [14]. At this point the connection between obesity and immunotherapy is becoming clearer. The devices with which tumors grow, and probably in viral infection such us COVID-19, in an overweight body are the source of immunomodulatory medications. The presence of PD-1 on the outside of T cells is beyond question, a result of obesity [15].

Acquired cellular immune surveillance is a precisely controlled series of processes and activities affecting particular T lymphocyte populations and subpopulations. The main obligation for the cytotoxic removal of virally
compromised and tumor cells rests with CD8+ CD3+ TcR+ [16]. One part of the regulatory arm of cellular immunity results in ‘exhausted T cells’ (Tex), which mainly belong to the CD8+ population and occur in persistent high-grade viral infection, such as the COVID-19 [17]. Tex is broadly divided into two subsets: at the initial and intermediate stage, they retain quasi-normal mitochondrial spare respiratory capacity, and are generally responsive to PD-1 blockade of the kind outlined above [18,19]. Tex at the more advanced level, has lower mitochondrial spare respiratory capacity and is terminally depleted and mostly unresponsive to PD-1 checkpoint immunotherapy blockade [20]. Generally speaking, the development of Tim-3 in Tex is similar to that of PD-1, as well as the output of IL-10, TNF-α and other cytokines that mediate apoptotic T cytopenia in some of these patients [21–23].

In patients with reported COVID-19, their data point to major T cytopenia in CD4+ and CD8+ T cells in circulation [24]. Such patients’ serum had considerably elevated amounts of IL-6, IL-10 and TNF-α. More analyzes found a steady rise in the subpopulation PD-1+ CD8+ and Tim-3+ CD8+ as patients progressed from prodromal to symptomatic COVID-19 needing intensive treatment [25,26]. Taken together, the profile mentioned indicates Tex emerging in patients with verified COVID-19.

In view of the fact that immune checkpoint inhibitors immunotherapy may restore cellular immunocompetence, as it previously proposed in the case of influenza infection, the patient undergoing immune checkpoint blockade could be more immunocompetent than cancer patients undergoing chemotherapy [27,28].

This immunotherapy focused on inflammatory cytokine neutralization, immunomodulation and passive viral neutralization may only decrease inflammation, inflammation-associated lung injury, or viral load, but can also avoid acute hospitalization and mechanical ventilation dependency, all of which are restricted options [29].

Conclusion

At this point, reducing the impact of health inequality on disease occurrence is impossible, not to mention the basic genetic rules for both obesity and morbidity and mortality correlated with COVID-19. Improvements in government policies based on enhancing population nutrition, which not only saves hundreds and even thousands of lives around the world in the coming months, should be expected. But still discourage future pandemics from swamping public systems that are already overrun with people with severe food shortages [30].

What the entire crisis has brought to our notice are the very disturbing health gaps that tend to grow year after year in many countries across the world. We hope that this pandemic will render any health gaps easy for everyone.

While no study has been done, and no vaccinations or antiviral therapeutic agents have been licensed to treat COVID-19 until now, the vaccinations may be effective due to the unique nature of the virus. In fact, current data on SARS-CoV and MERS-CoV immunotherapy carries the potential for usage in COVID-19.

Despite significant progress in the production of a monoclonal antibody-based passive immunotherapy for infection with coronavirus, there is no monoclonal antibody on the market. What limit the use of antibodies is that large-scale production of monoclonal antibodies is laborious, expensive and time-consuming for clinical application. Therefore, it is imperative to plan and build advanced protein development platforms and expression systems to provide effective monoclonal antibodies at an acceptable cost in a short time.

While there is an abundance of data in obesity-related inflammation and related diseases affecting a disordered immune system, further research is urgently needed to identify novel approaches for the prevention and treatment of obesity-linked diseases like COVID-19. Research demonstrates a combination of both immunotherapy and lifestyle-dependent treatments can reduce prevalence and improve obesity-related malignancy outcomes. New findings are also updated to exploit obesity for favorable benefits, although associated with several harmful cancer causes, provided the involved mechanisms are handled properly. In fact, a large body of literature relates to a ‘meta-inflammatory’ state of obese associated with a deficit in the immune response. It is important to understand how obesity shapes immune responses and how obesity can change both the responses to immunotherapy and the potential toxicity. Therefore, all this suggests a surprisingly positive association between obesity, COVID-19 and immunotherapy.

More studies may help to establish how obesity enhances PD-1+ CD8 T cells in a significant number of COVID-19 patients, and whether this mechanism often leads to a decreased occurrence of COVID-19 in obese patients.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

References
1. Gilbert GL. SARS, MERS and COVID-19-new threats; old lessons. *Int. J. Epidemiol.* doi:10.1093/ije/dyaa061 (2020) (Epub ahead of print).
2. Finelli C, Sommella L, Gioia S, La Sala N, Tarantino G. Should visceral fat be reduced to increase longevity? *Ageing Res. Rev.* 12(4), 996–1004 (2013).
3. Huang JF, Wang XB, Zheng K *et al.* Obesity hypoventilation syndrome and severe COVID-19. *Metabolism* 22, 154249 (2020).
4. Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Commentary: obesity: the “achilles heel” for COVID-19? *Metabolism* 108, 154251 (2020).
5. Belančić A, Kresočvac A, Rački V. Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. *Obes. Med.* 19, 100259 (2020).
6. de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. *Diabetes Metab. Syndr.* 14(4), 597–600 (2020).
7. Leung WKC, Yu AP, Lai CWK, Siu PM. Association of markers of proinflammatory phenotype and beige adipogenesis with metabolic syndrome in Chinese centrally obese adults. *J. Diabetes Res.* 2018, doi:10.1155/2018/8956509 (2018).
8. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. *Nat. Rev. Endocrinol.* 16(7), 341–342 (2020).
9. Yoo JH. Convalescent plasma therapy for corona virus disease 2019: a long way to go but worth trying. *J. Korean Med. Sci.* 35(14), e150 (2020).
10. Kolifarhood G, Aghaali M, Mozafar Saadati H *et al.* Epidemiological and clinical aspects of COVID-19; a narrative review. *Arch. Acad. Emerg. Med.* 8(1), e41 (2020).
11. Arnaldez FI, O’Day SJ, Drake CG *et al.* The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. *J. Immunother. Cancer.* 8(1), e000930 (2020).
12. Gaspanyan AY, Misra DP, Yessirkepov M, Zimba O. Perspectives of immune therapy in coronavirus disease 2019. *J. Korean Med. Sci.* 35(18), e176 (2020).
13. Finelli C. Obesity and immunotherapy: the surprisingly positive association! *Immunotherapy* 12(8), 541–544 (2020).
14. Chocarro de Erauso L, Zuazo M, Arasanz H *et al.* Resistance to PD-L1/PD-1 blockade immunotherapy: A tumor-intrinsic or tumor-extrinsic phenomenon? *Front Pharmacol.* 11, 441 (2020).
15. Yang YSH, Li ZL, Shih YJ *et al.* Herbal medicines attenuate PD-L1 expression to induce anti-proliferation in obesity-related cancers. *Nutrients* 11(12), 2979 (2019).
16. Zatterale F, Longo M, Naderi J *et al.* Chronic adipose tissue inflammation linking obesity to insulin resistance and Type 2 diabetes. *Front Physiol.* 10, 1607 (2020).
17. Hanley B, Roufosse CA, Osborn M, Naresh KN. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date. *Br. J. Haematol.* 189(6), 1062–1063 (2020).
18. Miller BC, Sen DR, Al Abooly R *et al.* Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. *Nat. Immunol.* 20(3), 326–336 (2019).
19. Cullen JG, McQuilten HA, Quinn KM *et al.* CD4 + T help promotes influenza virus-specific CD8 + T cell memory by limiting metabolic dysfunction. *Proc. Natl Acad. Sci. USA* 116(10), 4481–4488 (2019).
20. Wang WJ, Salazar Garcia MD, Deutsch G *et al.* PD-1 and PD-L1 expression on T cell subsets in women with unexplained recurrent pregnancy losses. *Am. J. Reprod. Immunol.* 83(5), e13230 (2020).
21. Kim K, Park S, Park SY *et al.* Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. *Genome Med.* 12(1), 22 (2020).
22. Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. *Nat. Rev. Immunol.* 20(3), 173–185 (2020).
23. Beltra JC, Manne S, Abdel-Hakeem MS *et al.* Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. *Immunity* 52(5), 825–841 (2020).
24. Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. *Blood Cells Mol. Dis.* 83, 102437 (2020).
25. Diao B, Wang C, Tan Y et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). *Front Immunol.* 11, 827 (2020).

26. Moon C. Fighting COVID-19 exhausts T cells. *Nat. Rev. Immunol.* 20(5), 277 (2020).

27. Bersanelli M, Scala S, Affanni P et al. Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients. *Immunotherapy* 12(2), 105–110 (2020).

28. Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. *Immunotherapy* 12(5), 269–273 (2020).

29. Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, Bayry J. Adjunct immunotherapies for the management of severely ill COVID-19 patients. *Cell Rep. Med.* 1(2), 100016 (2020).

30. Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. *Brain Behav. Immun.* 87, 53–54 (2020).